An Individual Patient Data Meta-Analysis with Colombian Studies on the Effect of Dark Chocolate Consumption on Cardiovascular Risk Parameters

被引:0
|
作者
Alvarez, Leidy [1 ]
Contreras, Javier [2 ]
Giraldo, Monica [3 ]
机构
[1] Univ Antioquia, Grp Clin Epidemiol, Medellin 05001, Colombia
[2] Univ Antioquia, Dept Pediatrician, Grp Clin Epidemiol, Medellin 05001, Colombia
[3] Univ Antioquia, Dept Microbiol & Parasitol, Grp Primary Immunodeficiencies, Medellin 05001, Colombia
关键词
D O I
10.1155/2020/3419598
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background. It is postulated that cocoa solids possess cardioprotective capacity by various mechanisms. In the different cocoa studies evaluating cardiovascular disease, there are no conclusive data on the role it plays in controlling the lipid profile and anthropometric variables, perhaps because the concentration of cocoa, the geographical origin of the population, and the different concentrations supplied lead to a high heterogeneity of results. This study aims to estimate the effect of consuming cocoa-rich chocolate compared to placebo on the lipid profile and anthropometric variables based on data from three clinical trials conducted in Colombia. Methods. Meta-analysis of individual data from three randomized clinical trials conducted in Colombia. The entire population of the primary studies was included, which was reassigned into intervention groups if they consumed 50 grams of 70% concentrated cocoa or placebo, which was considered to be cocoa-free or with a concentration less than 50 grams. The variables at the beginning of the study were analyzed with medians, interquartile ranges, means, and deviations according to whether they met the normality assumption. Multiple imputations were used to manage missing data and were analyzed using the two approaches proposed for this type of study, that of one and two stages. In the two-stage approach, the data were weighted on a conventional Forrest plot, while in the one-stage approach, linear regressions with mixed models were applied. This study is governed by the regulations described in the 2013 Declaration of Helsinki and by article 11 of Resolution 8430 of 1993, which classifies it as a risk-free study. Results. A total of 275 participants were included, who consumed cocoa or placebo for 81 days on average; 52.7% were female and few smoked at the time of the intervention (31/275). Physical activity performed in number of hours per week was comparable between the intervention groups. When evaluating total cholesterol, low-density cholesterol (LDL), high-density cholesterol (HDL), triglycerides, abdominal circumference, and final body mass index with both the one-stage and two-stage approaches, there were no significant differences between the two groups. Conclusions. According to the results obtained in the meta-analysis, the consumption of cocoa in the Colombian population does not seem to significantly modify variables such as lipid profile, abdominal circumference, and body mass index. This conclusion according to the quality of the evidence has a weak recommendation and a low-to-moderate certainty. However, the analysis through the two proposed approaches yielded similar results.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Chocolate consumption and risk of cardiovascular diseases: a meta-analysis of prospective studies
    Ren, Yongcheng
    Liu, Yu
    Sun, Xi-Zhuo
    Wang, Bing-Yuan
    Zhao, Yang
    Liu, De-Chen
    Zhang, Dong-Dong
    Liu, Xue-Jiao
    Zhang, Rui-Yuan
    Sun, Hao-Hang
    Liu, Fei-Yan
    Chen, Xu
    Cheng, Cheng
    Liu, Lei-Lei
    Zhou, Qiong-Gui
    Zhang, Ming
    Hu, Dong-Sheng
    [J]. HEART, 2019, 105 (01) : 49 - 55
  • [2] Chocolate Consumption and Risk of Heart Failure: A Meta-Analysis of Prospective Studies
    Gong, Fei
    Yao, Shuyuan
    Wan, Jing
    Gan, Xuedong
    [J]. NUTRIENTS, 2017, 9 (04)
  • [3] Chocolate consumption and risk of heart failure: a meta-analysis of prospective cohort studies
    Krittanawong, C.
    Tunhasiriwet, A.
    Rodriguez, M.
    Yue, B.
    Virk, H. U. Hassan
    Herzog, E.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 : 1114 - 1114
  • [4] Chocolate consumption and risk of atrial fibrillation: Two cohort studies and a meta-analysis
    Larsson, Susanna C.
    Drca, Nikola
    Jensen-Urstad, Mats
    Wolk, Alicja
    [J]. AMERICAN HEART JOURNAL, 2018, 195 : 86 - 90
  • [5] Budesonide and the risk of pneumonia: a meta-analysis of individual patient data
    Sin, Don D.
    Tashkin, Donald
    Zhang, Xuekui
    Radner, Finn
    Sjobring, Ulf
    Thoren, Anders
    Calverley, Peter M. A.
    Rennard, Stephen I.
    [J]. LANCET, 2009, 374 (9691): : 712 - 719
  • [6] Risk of Fracture with Thiazolidinediones: An Individual Patient Data Meta-Analysis
    Bazelier, Marloes T.
    de Vries, Frank
    Vestergaard, Peter
    Herings, Ron M. C.
    Gallagher, Arlene M.
    Leufkens, Hubert G. M.
    van Staa, Tjeerd-Pieter
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 286 - 287
  • [7] Cheese consumption and risk of cardiovascular disease: a meta-analysis of prospective studies
    Guo-Chong Chen
    Yan Wang
    Xing Tong
    Ignatius M. Y. Szeto
    Gerrit Smit
    Zeng-Ning Li
    Li-Qiang Qin
    [J]. European Journal of Nutrition, 2017, 56 : 2565 - 2575
  • [8] Cheese consumption and risk of cardiovascular disease: a meta-analysis of prospective studies
    Chen, Guo-Chong
    Wang, Yan
    Tong, Xing
    Szeto, Ignatius M. Y.
    Smit, Gerrit
    Li, Zeng-Ning
    Qin, Li-Qiang
    [J]. EUROPEAN JOURNAL OF NUTRITION, 2017, 56 (08) : 2565 - 2575
  • [9] The effect of cocoa/dark chocolate consumption on lipid profile, glycemia, and blood pressure in diabetic patients: A meta-analysis of observational studies
    Darand, Mina
    Hajizadeh Oghaz, Masoomeh
    Hadi, Amir
    Atefi, Masoumeh
    Amani, Reza
    [J]. PHYTOTHERAPY RESEARCH, 2021, 35 (10) : 5487 - 5501
  • [10] Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data
    Antonia C. Wang
    Ulf Stellmacher
    Jennifer Schumi
    Nora Tu
    Paul-Egbert Reimitz
    [J]. American Journal of Cardiovascular Drugs, 2016, 16 : 427 - 437